{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:11:24Z","timestamp":1778033484566,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-025-02666-z","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T13:19:45Z","timestamp":1747919985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Defining occult disease in glioblastoma using spectroscopic MRI: implications for clinical target volume delineation"],"prefix":"10.1186","volume":"20","author":[{"given":"Jonathan B.","family":"Bell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sulaiman","family":"Sheriff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Z.","family":"Goryawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaylie","family":"Cullison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Azzam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Meshman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew C.","family":"Abramowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Ivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macarena I.","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Mellon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"issue":"1","key":"2666_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11060-019-03152-9","volume":"143","author":"TJ Kruser","year":"2019","unstructured":"Kruser TJ, Bosch WR, Badiyan SN, Bovi JA, Ghia AJ, Kim MM, et al. NRG brain tumor specialists consensus guidelines for glioblastoma contouring. J Neurooncol. 2019;143(1):157\u201366.","journal-title":"J Neurooncol"},{"issue":"1","key":"2666_CR2","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.ijrobp.2019.06.539","volume":"105","author":"C Tsien","year":"2019","unstructured":"Tsien C, Pugh S, Dicker AP, Raizer JJ, Matuszak MM, Lallana E, et al. Randomized phase II trial of Re-Irradiation and concurrent bevacizumab versus bevaziumab alone as treatment for recurrent glioblastoma (NRG oncology\/rtog 1205): initial outcomes and RT plan quality report. Int J Radiat Oncol Biol Phys. 2019;105(1):S78.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2666_CR3","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ijrobp.2014.03.049","volume":"90","author":"NA Parra","year":"2014","unstructured":"Parra NA, Maudsley AA, Gupta RK, Ishkanian F, Huang K, Walker GR, et al. Volumetric spectroscopic imaging of glioblastoma multiforme radiation treatment volumes. Int J Radiat Oncol Biol Phys. 2014;90(2):376\u201384.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"2666_CR4","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00701-012-1418-x","volume":"154","author":"J Guo","year":"2012","unstructured":"Guo J, Yao C, Chen H, Zhuang D, Tang W, Ren G, et al. The relationship between Cho\/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas. Acta Neurochir (Wien). 2012;154(8):1361\u201370. discussion 70.","journal-title":"Acta Neurochir (Wien)"},{"issue":"8","key":"2666_CR5","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/neuonc\/now036","volume":"18","author":"JS Cordova","year":"2016","unstructured":"Cordova JS, Shu HK, Liang Z, Gurbani SS, Cooper LA, Holder CA, et al. Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients. Neuro Oncol. 2016;18(8):1180\u20139.","journal-title":"Neuro Oncol"},{"issue":"3","key":"2666_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/tomography10030033","volume":"10","author":"AC Rejimon","year":"2024","unstructured":"Rejimon AC, Ramesh KK, Trivedi AG, Huang V, Schreibmann E, Weinberg BD, et al. The utility of spectroscopic MRI in stereotactic biopsy and radiotherapy guidance in newly diagnosed glioblastoma. Tomography. 2024;10(3):428\u201343.","journal-title":"Tomography"},{"issue":"1","key":"2666_CR7","first-page":"vdac006","volume":"4","author":"K Ramesh","year":"2022","unstructured":"Ramesh K, Mellon EA, Gurbani SS, Weinberg BD, Schreibmann E, Sheriff SA, et al. A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma. Neurooncol Adv. 2022;4(1):vdac006.","journal-title":"Neurooncol Adv"},{"issue":"1","key":"2666_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13014-023-02219-2","volume":"18","author":"JB Bell","year":"2023","unstructured":"Bell JB, Jin W, Goryawala MZ, Azzam GA, Abramowitz MC, Diwanji T, et al. Delineation of recurrent glioblastoma by whole brain spectroscopic magnetic resonance imaging. Radiat Oncol. 2023;18(1):37.","journal-title":"Radiat Oncol"},{"issue":"8","key":"2666_CR9","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"issue":"4","key":"2666_CR10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/nbm.1025","volume":"19","author":"AA Maudsley","year":"2006","unstructured":"Maudsley AA, Darkazanli A, Alger JR, Hall LO, Schuff N, Studholme C, et al. Comprehensive processing, display and analysis for in vivo MR spectroscopic imaging. NMR Biomed. 2006;19(4):492\u2013503.","journal-title":"NMR Biomed"},{"key":"2666_CR11","doi-asserted-by":"publisher","first-page":"592155","DOI":"10.3389\/fneur.2020.592155","volume":"11","author":"Y Cui","year":"2020","unstructured":"Cui Y, Zeng W, Jiang H, Ren X, Lin S, Fan Y, et al. Higher Cho\/NAA ratio in postoperative peritumoral edema zone is associated with earlier recurrence of glioblastoma. Front Neurol. 2020;11:592155.","journal-title":"Front Neurol"},{"issue":"5","key":"2666_CR12","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/jmri.20039","volume":"19","author":"J Oh","year":"2004","unstructured":"Oh J, Henry RG, Pirzkall A, Lu Y, Li X, Catalaa I, et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging. 2004;19(5):546\u201354.","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"2666_CR13","first-page":"249","volume":"11","author":"D Di Perri","year":"2024","unstructured":"Di Perri D, Hofstede D, Hartgerink D, Terhaag K, Houben R, Postma AA, et al. Impact of clinical target volume margin reduction in glioblastoma patients treated with concurrent chemoradiation. Neurooncol Pract. 2024;11(3):249\u201354.","journal-title":"Neurooncol Pract"},{"key":"2666_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1748-717X-9-130","volume":"9","author":"BJ Gebhardt","year":"2014","unstructured":"Gebhardt BJ, Dobelbower MC, Ennis WH, Bag AK, Markert JM, Fiveash J. B. Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent Temozolomide. Radiat Oncol. 2014;9:130.","journal-title":"Radiat Oncol"},{"issue":"1","key":"2666_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.prro.2018.06.001","volume":"9","author":"K Guram","year":"2019","unstructured":"Guram K, Smith M, Ginader T, Bodeker K, Pelland D, Pennington E, et al. Using Smaller-Than-Standard radiation treatment margins does not change survival outcomes in patients with High-Grade gliomas. Pract Radiat Oncol. 2019;9(1):16\u201323.","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"2666_CR16","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.ijrobp.2007.08.015","volume":"70","author":"R Mayer","year":"2008","unstructured":"Mayer R, Sminia P. Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys. 2008;70(5):1350\u201360.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2666_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","volume":"47","author":"E Shaw","year":"2000","unstructured":"Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90\u2013\u200905. Int J Radiat Oncol Biol Phys. 2000;47(2):291\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"2666_CR18","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2009.25.6941","volume":"28","author":"SE Fogh","year":"2010","unstructured":"Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol. 2010;28(18):3048\u201353.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2666_CR19","doi-asserted-by":"publisher","first-page":"100987","DOI":"10.1016\/j.adro.2022.100987","volume":"7","author":"W Hager","year":"2022","unstructured":"Hager W, Lazzeroni M, Astaraki M, Toma-Dasu. I. CTV delineation for High-Grade gliomas: is there agreement with tumor cell invasion models?? Adv Radiat Oncol. 2022;7(5):100987.","journal-title":"Adv Radiat Oncol"},{"issue":"3","key":"2666_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.18383\/j.tom.2017.00009","volume":"3","author":"MD Garrett","year":"2017","unstructured":"Garrett MD, Yanagihara TK, Yeh R, McKhann GM, Sisti MB, Bruce JN, et al. Monitoring radiation treatment effects in glioblastoma: FLAIR volume as significant predictor of survival. Tomography. 2017;3(3):131\u201337.","journal-title":"Tomography"},{"key":"2666_CR21","first-page":"100697","volume":"44","author":"SM Christ","year":"2024","unstructured":"Christ SM, Youssef G, Tanguturi SK, Cagney D, Shi D, McFaline-Figueroa JR, et al. Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: target delineation, outcomes and patterns of recurrence. Clin Transl Radiat Oncol. 2024;44:100697.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"2666_CR22","first-page":"vdab060","volume":"3","author":"P Talati","year":"2021","unstructured":"Talati P, El-Abtah M, Kim D, Dietrich J, Fu M, Wenke M, et al. MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma. Neurooncol Adv. 2021;3(1):vdab060.","journal-title":"Neurooncol Adv"},{"issue":"1","key":"2666_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/neuonc\/noad119","volume":"26","author":"A Laprie","year":"2024","unstructured":"Laprie A, Noel G, Chaltiel L, Truc G, Sunyach MP, Charissoux M, et al. Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial). Neuro Oncol. 2024;26(1):153\u201363.","journal-title":"Neuro Oncol"},{"issue":"1","key":"2666_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/neuonc\/noad166","volume":"26","author":"HG Shu","year":"2024","unstructured":"Shu HG, Shim H. SPECTRO GLIO trial aftermath: where do we go from here? Neuro Oncol. 2024;26(1):164\u201365.","journal-title":"Neuro Oncol"},{"key":"2666_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13014-016-0665-z","volume":"11","author":"MD Piroth","year":"2016","unstructured":"Piroth MD, Galldiks N, Pinkawa M, Holy R, Stoffels G, Ermert J, et al. Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume. Radiat Oncol. 2016;11:87.","journal-title":"Radiat Oncol"},{"issue":"4","key":"2666_CR26","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.prro.2018.01.006","volume":"8","author":"AR Hayes","year":"2018","unstructured":"Hayes AR, Jayamanne D, Hsiao E, Schembri GP, Bailey DL, Roach PJ, et al. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. Pract Radiat Oncol. 2018;8(4):230\u201338.","journal-title":"Pract Radiat Oncol"},{"key":"2666_CR27","doi-asserted-by":"publisher","first-page":"110386","DOI":"10.1016\/j.radonc.2024.110386","volume":"198","author":"A Holzgreve","year":"2024","unstructured":"Holzgreve A, Nitschmann A, Maier SH, Buttner M, Schonecker S, Marschner SN, et al. FET PET-based target volume delineation for the radiotherapy of glioblastoma: A pictorial guide to help overcome methodological pitfalls. Radiother Oncol. 2024;198:110386.","journal-title":"Radiother Oncol"},{"key":"2666_CR28","doi-asserted-by":"publisher","first-page":"109663","DOI":"10.1016\/j.radonc.2023.109663","volume":"184","author":"M Niyazi","year":"2023","unstructured":"Niyazi M, Andratschke N, Bendszus M, Chalmers AJ, Erridge SC, Galldiks N, et al. ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma. Radiother Oncol. 2023;184:109663.","journal-title":"Radiother Oncol"},{"key":"2666_CR29","doi-asserted-by":"publisher","first-page":"1059712","DOI":"10.3389\/fmed.2023.1059712","volume":"10","author":"S Chiesa","year":"2023","unstructured":"Chiesa S, Russo R, Beghella Bartoli F, Palumbo I, Sabatino G, Cannata MC, et al. MRI-derived radiomics to guide post-operative management of glioblastoma: implication for personalized radiation treatment volume delineation. Front Med (Lausanne). 2023;10:1059712.","journal-title":"Front Med (Lausanne)"},{"issue":"19","key":"2666_CR30","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.3390\/jcm11195961","volume":"11","author":"S Dajani","year":"2022","unstructured":"Dajani S, Hill VB, Kalapurakal JA, Horbinski CM, Nesbit EG, Sachdev S, et al. Imaging of GBM in the age of molecular markers and MRI guided adaptive radiation therapy. J Clin Med. 2022;11(19):5961.","journal-title":"J Clin Med"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02666-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02666-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02666-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T13:19:46Z","timestamp":1747919986000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02666-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2666"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02666-z","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the University of Miami Institutional Review Board (IRB) (IRB #20190678). All patients provided written informed consent prior to enrolment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}